About
this research group
Over the past years, Nielka developed an own research focus 'Clinical pharmacology' at the department of Pharmacy in the Radboudumc. The overall aim of her research activities is to optimize anticancer treatment in oncology patients by recognizing and addressing interindividual differences and by developing approaches to keep the drugs available for all patients suffering from cancer.
Several study proposals have been granted, completed and resulted in:
- Optimized oncology patient care by identifying early treatment response biomarker and understanding the relation of these early response markers and drug exposure.
- Strategies proven feasible and safe to make oncolytic therapy better tolerable and affordable.
The research resulted in the successful completion of several PhD thesis’s and the recruitment of other PhDs to continue this work. As a hospital pharmacist and clinical pharmacologist focusing on oncology patient care, Nielka feels the obligation to generate freely accessible information and tools for safer cancer patient care. The
cancer drug interaction website is an example of a tool which helps patients, physicians and pharmacists to safer use the anticancer drugs in combinations with their other drugs.
For the last four years, Nielka is head of the Laboratory for therapeutic drug monitoring and research in which we develop and validate methods for quantifying drugs in human plasma, blood, urine and tissue. Under her supervision the laboratory received ISO15189 accreditation, research method development has accelerate and more research projects are supported.
Finally, this research group has a broad national and international network. It collaborates with the Medical Oncology, Urology and Surgery departments within and outside our clinic and conduct studies with groups from Australia, USA and France.
NL
DE
